Global pharmaceutical giant Lupin Limited has made a significant entry into the U.S. contraceptive market with the launch of Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP, 0.3 mg/0.03 mg. This follows the company’s successful receipt of approval from the United States Food and Drug Administration (U.S. FDA).

Turqoz: A Generic Equivalent to Lo/Ovral-28

Turqoz is the generic equivalent of Lo/Ovral-28 (Norgestrel and Ethinyl Estradiol) Tablets, 0.3 mg/0.03 mg, originally developed by Wyeth Pharmaceuticals LLC. As a contraceptive drug, Turqoz is indicated for the prevention of pregnancy, offering a vital healthcare option for women.

Market Potential in the U.S.

The Norgestrel and Ethinyl Estradiol Tablets USP, the Reference Listed Drug (RLD) Lo/Ovral-28, had estimated annual sales of USD 33 million in the U.S., according to IQVIA MAT October 2023. This figure highlights the significant market potential for Lupin’s Turqoz in the American healthcare market.

Lupin’s Commitment to Healthcare Solutions

Lupin’s launch of Turqoz in the U.S. market is a testament to the company’s commitment to expanding its portfolio in the healthcare sector. The availability of this generic contraceptive option underscores Lupin’s dedication to providing accessible and effective healthcare solutions globally.

With Turqoz, Lupin Limited is set to make a substantial impact in the U.S. pharmaceutical market, particularly in the domain of contraceptive drugs, further establishing its role as a leading player in global healthcare.

  Lo/Ovral-28, Lupin, Turqoz Tablets, US FDA, USA, Wyeth Pharmaceuticals